A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT03820726 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

435

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Diseases, Interstitial

Interventions

DRUG: Nintedanib

Sponsor

Boehringer Ingelheim